vs
Side-by-side financial comparison of BIODESIX INC (BDSX) and Guardant Health, Inc. (GH). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $28.8M, roughly 9.8× BIODESIX INC). BIODESIX INC runs the higher net margin — -13.8% vs -45.7%, a 31.8% gap on every dollar of revenue. On growth, BIODESIX INC posted the faster year-over-year revenue change (40.8% vs 39.4%). BIODESIX INC produced more free cash flow last quarter ($692.0K vs $-54.2M). Over the past eight quarters, BIODESIX INC's revenue compounded faster (39.3% CAGR vs 29.2%).
Biodesix Inc is a molecular diagnostics enterprise specializing in developing and commercializing innovative blood-based testing solutions for oncology and infectious disease fields. It primarily serves healthcare providers, biopharmaceutical partners and patients across North America, with core business covering personalized medicine products that support clinical decision making.
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
BDSX vs GH — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $28.8M | $281.3M |
| Net Profit | $-4.0M | $-128.5M |
| Gross Margin | — | 64.6% |
| Operating Margin | -6.8% | -43.0% |
| Net Margin | -13.8% | -45.7% |
| Revenue YoY | 40.8% | 39.4% |
| Net Profit YoY | 51.8% | -15.8% |
| EPS (diluted) | $-3.35 | $-1.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $28.8M | $281.3M | ||
| Q3 25 | $21.8M | $265.2M | ||
| Q2 25 | $20.0M | $232.1M | ||
| Q1 25 | $18.0M | $203.5M | ||
| Q4 24 | $20.4M | $201.8M | ||
| Q3 24 | $18.2M | $191.5M | ||
| Q2 24 | $17.9M | $177.2M | ||
| Q1 24 | $14.8M | $168.5M |
| Q4 25 | $-4.0M | $-128.5M | ||
| Q3 25 | $-8.7M | $-92.7M | ||
| Q2 25 | $-11.5M | $-99.9M | ||
| Q1 25 | $-11.1M | $-95.2M | ||
| Q4 24 | $-8.3M | $-111.0M | ||
| Q3 24 | $-10.3M | $-107.8M | ||
| Q2 24 | $-10.8M | $-102.6M | ||
| Q1 24 | $-13.6M | $-115.0M |
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | 64.7% | ||
| Q2 25 | — | 65.0% | ||
| Q1 25 | — | 63.3% | ||
| Q4 24 | — | 61.6% | ||
| Q3 24 | — | 61.1% | ||
| Q2 24 | — | 59.1% | ||
| Q1 24 | — | 61.2% |
| Q4 25 | -6.8% | -43.0% | ||
| Q3 25 | -32.4% | -37.3% | ||
| Q2 25 | -48.6% | -45.9% | ||
| Q1 25 | -50.9% | -54.6% | ||
| Q4 24 | -32.5% | -62.4% | ||
| Q3 24 | -47.3% | -61.3% | ||
| Q2 24 | -46.0% | -56.8% | ||
| Q1 24 | -74.4% | -59.2% |
| Q4 25 | -13.8% | -45.7% | ||
| Q3 25 | -40.0% | -35.0% | ||
| Q2 25 | -57.3% | -43.0% | ||
| Q1 25 | -61.8% | -46.8% | ||
| Q4 24 | -40.4% | -55.0% | ||
| Q3 24 | -56.5% | -56.3% | ||
| Q2 24 | -60.3% | -57.9% | ||
| Q1 24 | -91.9% | -68.2% |
| Q4 25 | $-3.35 | $-1.01 | ||
| Q3 25 | $-1.16 | $-0.74 | ||
| Q2 25 | $-0.08 | $-0.80 | ||
| Q1 25 | $-0.08 | $-0.77 | ||
| Q4 24 | $-5.02 | $-0.90 | ||
| Q3 24 | $-1.40 | $-0.88 | ||
| Q2 24 | $-0.08 | $-0.84 | ||
| Q1 24 | $-0.14 | $-0.94 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $19.0M | $378.2M |
| Total DebtLower is stronger | $50.0M | $1.5B |
| Stockholders' EquityBook value | $-2.5M | $-99.3M |
| Total Assets | $87.5M | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $19.0M | $378.2M | ||
| Q3 25 | $16.6M | $580.0M | ||
| Q2 25 | $20.7M | $629.1M | ||
| Q1 25 | $17.6M | $698.6M | ||
| Q4 24 | $26.2M | $525.5M | ||
| Q3 24 | $31.4M | $585.0M | ||
| Q2 24 | $42.2M | $933.7M | ||
| Q1 24 | $11.5M | $1.0B |
| Q4 25 | $50.0M | $1.5B | ||
| Q3 25 | $50.0M | $1.1B | ||
| Q2 25 | $50.0M | $1.1B | ||
| Q1 25 | $40.0M | $1.1B | ||
| Q4 24 | $40.0M | $1.1B | ||
| Q3 24 | $40.0M | — | ||
| Q2 24 | $40.1M | — | ||
| Q1 24 | $40.1M | — |
| Q4 25 | $-2.5M | $-99.3M | ||
| Q3 25 | $-1.7M | $-354.5M | ||
| Q2 25 | $1.1M | $-305.5M | ||
| Q1 25 | $11.1M | $-250.8M | ||
| Q4 24 | $20.9M | $-139.6M | ||
| Q3 24 | $27.9M | $-60.1M | ||
| Q2 24 | $36.3M | $-1.6M | ||
| Q1 24 | $-5.5M | $68.3M |
| Q4 25 | $87.5M | $2.0B | ||
| Q3 25 | $88.7M | $1.3B | ||
| Q2 25 | $87.7M | $1.3B | ||
| Q1 25 | $86.2M | $1.3B | ||
| Q4 24 | $97.2M | $1.5B | ||
| Q3 24 | $102.7M | $1.5B | ||
| Q2 24 | $115.8M | $1.6B | ||
| Q1 24 | $87.2M | $1.7B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 43.95× | — | ||
| Q1 25 | 3.62× | — | ||
| Q4 24 | 1.92× | — | ||
| Q3 24 | 1.44× | — | ||
| Q2 24 | 1.10× | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $778.0K | $-26.4M |
| Free Cash FlowOCF − Capex | $692.0K | $-54.2M |
| FCF MarginFCF / Revenue | 2.4% | -19.3% |
| Capex IntensityCapex / Revenue | 0.3% | 9.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-23.5M | $-233.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $778.0K | $-26.4M | ||
| Q3 25 | $-8.9M | $-35.4M | ||
| Q2 25 | $-6.6M | $-60.3M | ||
| Q1 25 | $-8.6M | $-62.7M | ||
| Q4 24 | $-4.1M | $-64.5M | ||
| Q3 24 | $-10.7M | $-51.1M | ||
| Q2 24 | $-18.6M | $-94.0M | ||
| Q1 24 | $-15.3M | $-30.3M |
| Q4 25 | $692.0K | $-54.2M | ||
| Q3 25 | $-8.9M | $-45.8M | ||
| Q2 25 | $-6.6M | $-65.9M | ||
| Q1 25 | $-8.7M | $-67.1M | ||
| Q4 24 | $-4.9M | $-83.4M | ||
| Q3 24 | $-10.9M | $-55.3M | ||
| Q2 24 | $-20.5M | $-99.1M | ||
| Q1 24 | $-15.5M | $-37.2M |
| Q4 25 | 2.4% | -19.3% | ||
| Q3 25 | -41.0% | -17.3% | ||
| Q2 25 | -33.1% | -28.4% | ||
| Q1 25 | -48.3% | -33.0% | ||
| Q4 24 | -24.2% | -41.3% | ||
| Q3 24 | -60.1% | -28.9% | ||
| Q2 24 | -114.3% | -55.9% | ||
| Q1 24 | -104.9% | -22.1% |
| Q4 25 | 0.3% | 9.9% | ||
| Q3 25 | 0.2% | 3.9% | ||
| Q2 25 | 0.3% | 2.4% | ||
| Q1 25 | 0.4% | 2.2% | ||
| Q4 24 | 4.1% | 9.4% | ||
| Q3 24 | 1.3% | 2.2% | ||
| Q2 24 | 10.7% | 2.9% | ||
| Q1 24 | 1.6% | 4.1% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BDSX
| Diagnostic Tests | $25.1M | 87% |
| Development Services | $3.6M | 13% |
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
